Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Jamie ToombsHenrik Zetterberg

Abstract

We tested the hypothesis that the amyloid β (Aβ) peptide ratios are more stable than Aβ42 alone when biofluids are exposed to two preanalytical conditions known to modify measurable Aβ concentration. Human cerebrospinal fluid (CSF) and culture media (CM) from human cortical neurons were exposed to a series of volumes and polypropylene surfaces. Aβ42, Aβ40, and Aβ38 peptide concentrations were measured using a multiplexed electrochemiluminescence immunoassay. Data were analyzed using mixed models in R. Decrease of measurable Aβ peptide concentrations was exaggerated in longer peptides, affecting the Aβ42:Aβ40 and Aβ42:Aβ38 ratios. However, the effect size of surface treatment was reduced in Aβ peptide ratios versus Aβ42 alone. For Aβ42:Aβ40, the effect was reduced by approximately 50% (volume) and 75% (transfer) as compared to Aβ42 alone. Use of Aβ ratios, in conjunction with concentrations, may mitigate confounding factors and assist the clinical diagnostic process for Alzheimer's disease.

References

Nov 15, 2005·Chemphyschem : a European Journal of Chemical Physics and Physical Chemistry·Sandra RochaGerald Brezesinski
Mar 22, 2007·Dementia and Geriatric Cognitive Disorders·Oskar HanssonKaj Blennow
Mar 31, 2007·Clinical Chemistry·Thierry S M ReijnMarcel M Verbeek
Jan 27, 2010·The Mount Sinai Journal of Medicine, New York·Daniel P Perl
Aug 28, 2010·International Journal of Alzheimer's Disease·Maria BjerkeKaj Blennow
Oct 22, 2011·PloS One·Bradley MooresZoya Leonenko
Oct 26, 2011·Journal of Neurochemistry·J Randall SlemmonKaj Blennow
Apr 13, 2012·Journal of Alzheimer's Disease : JAD·Armand Perret-LiaudetSylvain Lehmann
May 31, 2012·International Journal of Alzheimer's Disease·Teresa A EllisJeffrey F Waring
Jul 5, 2012·Cold Spring Harbor Perspectives in Medicine·Eva-Maria Mandelkow, Eckhard Mandelkow
Sep 7, 2012·Cold Spring Harbor Perspectives in Medicine·Kaj BlennowAnne M Fagan
Oct 5, 2012·Journal of Alzheimer's Disease : JAD·Nathalie Le BastardSebastiaan Engelborghs
Mar 30, 2013·Nature Methods·Brian M MurphyMark I Fitchmun
Apr 30, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Niklas MattssonUNKNOWN Alzheimer's Association QC Program Work Group
Aug 14, 2013·Clinical Chemistry and Laboratory Medicine : CCLM·Jamie ToombsHenrik Zetterberg
Aug 22, 2013·Protein Science : a Publication of the Protein Society·Amber N MurrayJeffery W Kelly
Jan 30, 2014·Alzheimer's Research & Therapy·Jamie ToombsHenrik Zetterberg
May 23, 2014·Lancet Neurology·Bruno DuboisJeffrey L Cummings
Jun 14, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Massimo S FiandacaHoward J Federoff
Jun 19, 2014·Proceedings of the National Academy of Sciences of the United States of America·Georg MeislTuomas P J Knowles
Jun 25, 2014·PloS One·Stephanie J B VosCharlotte E Teunissen
Feb 6, 2015·Current Alzheimer Research·Manivannan YegambaramRolf U Halden
Apr 30, 2015·Cell Reports·Steven MooreFrederick J Livesey
Apr 5, 2016·Annals of Clinical and Translational Neurology·Shorena JanelidzeOskar Hansson
Jun 30, 2016·Journal of the American Chemical Society·Michael T ColvinRobert G Griffin
Jul 30, 2016·Proceedings of the National Academy of Sciences of the United States of America·Marielle Aulikki WältiRoland Riek
Jan 7, 2017·Journal of Alzheimer's Disease : JAD·Jamie ToombsHenrik Zetterberg

❮ Previous
Next ❯

Citations

Jul 22, 2019·Alzheimer's Research & Therapy·Shorena JanelidzeOskar Hansson
Oct 2, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Ashvini KeshavanJonathan M Schott
Aug 30, 2019·Annals of Clinical and Translational Neurology·Daniel AlcoleaAlberto Lleó
Feb 19, 2021·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Ashvini KeshavanJonathan M Schott
Apr 1, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Oskar HanssonKaj Blennow
May 23, 2021·Alzheimer's Research & Therapy·Marine TournissacFrédéric Calon
May 25, 2021·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Michelle R CampbellAlicia Algeciras-Schimnich

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.